Post-Authorization Safety Study (PASS) of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK2340272A) in the United Kingdom.

Trial Profile

Post-Authorization Safety Study (PASS) of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK2340272A) in the United Kingdom.

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Nov 2012

At a glance

  • Drugs Influenza A virus vaccine-H1N1 (Primary)
  • Indications Influenza A virus H1N1 subtype
  • Focus Adverse reactions
  • Acronyms H1N1 PASS UK
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 16 Mar 2012 Actual end date changed from May 2011 to Apr 2011 as reported by ClinicalTrials.gov.
    • 27 May 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
    • 27 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top